Piritrexim
(2,4-diamino-6-(2,5-dimethoxybenzyl)-5-methylpyridol [2,3-d] pyrimidine; BW301U) is a lipid-soluble antifolate which, like methotrexate, has a potent capacity to inhibit dihydrofolate reductase (Sedwick et al., 1982; Sigel et al., 1987) . There are, however, several differences between piritrexim and methotrexate. Piritrexim (PTX) is more lipophylic, enters cells rapidly and is not polyglutamated intracellularly, in contrast to methotrexate (Duch et al., 1982) . In the human tumour cell cloning assay the antitumour activity of piritrexim was found to be favourable when compared with methotrexate in lung, ovary, colon, and breast cancer (Marshall et al., 1985; Neuenfeldt et al., 1982) . Piritrexim was also capable of inhibiting the growth of several types of MTX resistant cells (Sedwick et al., 1982) .
Intravenous administration caused severe peripheral vein phlebitis (Weiss et al., 1989) , and for this reason more attention was paid to the oral route. Tumour responses have been observed in phase II studies in melanoma, non-small cell lung carcinoma, bladder carcinoma, and head and neck cancer (Feun et al., 1991; Kris et al., 1987; De Wit et al., 1993; Uen et al., 1992) .
Methotrexate is effective as a single agent in metastatic breast cancer (Carter, 1976) , and many patients currently receive methotrexate in first line combination therapy. Therefore, treatment with piritrexim, which could potentially also circumvent methotrexate resistance, could be of value in patients previously treated for breast carcinoma.
We therefore performed a multicenter phase II study with oral piritrexim in patients with locally advanced or metastatic breast cancer. The regimen was designed to entail the optimal dose for individual patients. In a limited number of patients PTX pharmacokinetics were evaluated on days one and four.
Patients and methods

Patients
To be eligible for this study, patients were (first reduction; 225 mg/week), with provision for a second reduction to 25 mg twice daily for 3 days (first reduction; 225 mg/week), with provision for a second reduction to 25 mg twice daily for 3 days (150 mg/week). Patients were assessed weekly at the outpatient clinic to document toxicity (scored according to WHO criteria), and to make dose adjustments if necessary.
To be evaluable for response a patient had to receive at least four cycles of PTX. Tumour evaluations were performed, according to standard criteria, at entry and after every four cycles. In case of a tumour response, patients continued therapy until progression. Patients with SD at 12 weeks, continuation of the treatment was offered for another 4 weeks. In case of PD, patients were taken off study.
In three patients pharmacokinetic analysis was performed on the first and fourth day, i.e. the first and last dose, of the first cycle of PTX. Blood samples were obtained prior to an oral dose (25 mg) and then at 0.5, 1, 1.5, 2, 3, 4, 5 and 6 h after the dose. The blood samples were collected in heparinised tubes and placed on ice until the plasma was separated by centrifugation. Plasma samples were stored frozen at -20C until assayed. PTX was extracted from plasma by adding acetronitrile (2:1 containing internal standard Ro 31-0644 at 0.2 Lg ml-'). The mixture was vortexed for 10 s and centrifuged (8000 g for 5 min), the supernatant was evaporated to dryness and the residue was resuspended in running buffer. The concentration of PTX was determined as previously described (Dennis, 1990) . In short, the measurements were performed by reversed phase high liquid performance chromatography using a Waters C 18 yBondPak 10 cm x 8 mm radial packed column. Separations were achieved by eluting with a linear gradient of 14% to 33% acetronitrile in a 1% acetic acid solution over 15 min at a flow rate of 3 ml min-'. Detection was performed at 320 nm and identification was performed by chromatographic and spectral properties using a Waters photodiode array detector.
Pharmacokinetic parameters were determined by modelindependent methods. The AUC from time 0 to 6 h was derived by the trapezoidal method. The AUC from 0 to 6 h measured at steady state is presumed to be equivalent to the AUC extrapolated to infinity following a single dose (Gibaldi & Perrier, 1982) .
Results
Twenty-four patients were entered into this trial. The characteristics of these patients are outlined in Table I . In Figure 1 the number of cycles with initial PTX dose as well as with PTX dose escalation or de-escalation is shown. All patients 
Toxicity
The total number of treatment weeks was 200, median 7 (range 1-36). In 18 patients the dose was escalated by one step, in nine it could be escalated by two steps. In three patients the dose had to be de-escalated by one step ( Figure  1 ). The observed toxicity is summarised in Table II . Myelotoxicity was the most frequently observed toxicity. Leucopenia and thrombocytopenia grade 3/4 occurred in 38% of the patients sometime during treatment. It was of short duration with recovery usually occurring within a few days after treatment interruption, and never lasted for more than one week. There were no episodes of neutropenic fever or signs of clinical bleeding. In several patients grade 3/4 myelotoxicity developed within the first treatment week. In three patients treated for 12 weeks or more, a red blood cell transfusion was necessary because of symptomatic anaemia. There was no clear evidence that patients who received extensive previous chemotherapy and/or radiotherapy experienced more haematological toxicity than patients without extensive prior therapy, since two of the four patients who received no prior myelotoxic treatment experienced a grade 4 thrombocytopenia. Mild nausea and vomiting occurred in 33% of the patients, anti-emetic treatment (metoclopramide) was required in only a minority. In four patients a maculo papular rash developed during PTX, while grade 1 mucositis was seen in three patients.
Pharmacokinetics
The concentration time curves on day 1 and 4 of the first PTX cycle of three patients are shown in Figure 2 . Pharmacokinetic parameters are listed in Table III . PTX was rapidly absorbed, with the peak levels occurring 1 to 2 h after an oral dose. The peak plasma level, AUC, and half-life on the fourth dosing day seemed to be somewhat higher than on the first, although the range was wide. 
bMedian (range).
Peak levela A UCa (ig ml-') (tg ml' h-') 0.34 ± 0.27 1.27 ± 1.04 0.81 ± 0.53 2.56 ± 1.02
Discussion
Based on its in vitro properties, PTX was considered to be an interesting drug for patients with locally advanced or metastatic breast cancer. This phase II study was designed to evaluate the efficacy of orally administered PTX in a group of previously treated patients with advanced local or metastatic breast cancer. Our results indicate that when administered three times daily for 4 days, repeated weekly, PTX shows only minimal activity. One PR out of 21 evaluable patients (response rate 5% with a 95% confidence interval 0 to 24%) was observed. This is a low response rate when compared with single agent MTX therapy (Carter, 1976) . There is a limited number of phase II studies employing repeated daily dosing with oral PTX. These studies showed tumour responses in seven out of 31 patients with metastatic melanoma, one out of 31 non-small cell lung carcinoma patients, in 11 out of 29 patients with metastatic urothelial cancer, and nine of 33 with advanced head and neck cancer (Feun et al., 1991; Kris et al., 1987; De Wit et al., 1993; Uen et al., 1992) . These data suggest that for melanoma and urothelial cancer PTX might be superior to that of the mother compound methotrexate. However, this does not seem to be the case for breast cancer. It has been suggested that the superior effect of PTX compared with methotrexate could be due to differences in tissue distribution of the two drugs, with high PTX levels being seen in the skin and lung of the rat (Sigel et al., 1987) . In the present study PTX was generally well tolerated. The dose limiting toxicity was myelosuppression, especially thrombocytopenia. The onset of thrombocytopenia was rather suddenly, it sometimes occurred already after only one treatment course; while other patients could be treated with PTX for longer periods without signs of substantial myelotoxicity. Just as in the other studies with orally administered PTX, mild nausea and vomiting, skin rash and mucositis were observed. The large variations in toxicity experienced by different patients may well be due to varying PTX absorption. Formulation problems for intravenous administration and local infusion reactions have been the major reasons for initiating studies with the potentially attractive oral route. For methotrexate it is well known that, in contrast to most drugs, continuous low dose administration is more myelotoxic than a short term high intravenous dose. It cannot be excluded that high dose PTX intravenously administered might result in a better response rate.
In this study pharmacokinetics were performed after oral administration PTX plasma levels were determined on the first and last doses of the first cycle twice on different days. The results obtained for the PTX half-life (range 1.04 to 6.16h) are in agreement with literature (Laszlo et al., 1987; Adamson et al., 1990; Adamson et al., 1992) . Two studies in children with orally administered PTX revealed a half-life between 1.1 and 4.5 h (Adamson et al., 1990; Adamson et al., 1992) . In our study, just as in the pediatric study, it was found that PTX was rapidly absorpted with peak levels 0.5-2 h after drug administration. The PTX levels in the children's study with a similar regimen were not determined on a fixed day (Adamson et al., 1990; Adamson et al., 1992) . The present study is the first in which the pharmacokinetic on two fixed days of a cycle were studied. It shows that in all three patients the pharmacokinetics were different on day one and four. Higher peak and AUC values were found at the end of the cycle and the apparent elimination half-life tended to be longer. These data may indicate a broad variability in absorption of PTX through the cycle. In the two studies in which bioavailability was studied it was found that the systemic bioavailability of PTX varied by up to 50% between patients, most probably due to differences in drug absorption (Weiss et al., 1989; Adamson et al., 1992) .
In conclusion, the administered schedule of oral PTX in locally advanced and metastatic breast carcinoma showed a disappointing response rate. It is possible that the variable myelotoxicity might be a result of differences in bioavailability, giving rise to inter-and intra-patient variability of pharmacokinetic behaviour of PTX after oral administration. 
